Chronic systemic IL-1β exacerbates central neuroinflammation independently of the blood-brain barrier integrity

Journal of Neuroimmunology

Volumn 278, Issue , 2015, Pages 30-43

  Murta, Verónica ^a   Farías, María Isabel ^a   Pitossi, Fernando Juan ^a   Ferrari, Carina Cintia ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

Blood brain barrier; Interleukin 1 ; Multiple sclerosis; Neuroinflammation; Neutrophils; Systemic inflammation

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HLA ANTIGEN CLASS 2;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; AXONAL INJURY; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; DEMYELINATION; DISEASE EXACERBATION; INNATE IMMUNITY; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UPREGULATION; ADENOVIRIDAE; ANIMAL; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; LEUKOCYTE; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; TOXICITY; WISTAR RAT;

ADENOVIRIDAE; ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CYTOKINES; DRUG ADMINISTRATION ROUTES; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; LEUKOCYTES; LIVER; MALE; NEUTROPHILS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84920913062     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.11.023     Document Type: Article

References (125)

1. Aggelakis K., Zacharaki F., Dardiotis E., Xiromerisiou G., Tsimourtou V., Ralli S., Gkaraveli M., Bourpoulas D., Rodopoulou P., Papadimitriou A., Hadjigeorgiou G. Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in Greek multiple sclerosis (MS) patients with bout-onset MS. Neurol. Sci. 2010, 31:253-257.
2. Anthony D.C., Couch Y., Losey P., Evans M.C. The systemic response to brain injury and disease. Brain Behav. Immun. 2012, 26:534-540.
3. Argaw A.T., Zhang Y., Snyder B.J., Zhao M.L., Kopp N., Lee S.C., Raine C.S., Brosnan C.F., John G.R. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J. Immunol. 2006, 177:5574-5584.
4. Banks W.A., Kastin A.J., Broadwell R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2:241-248.
5. Bebo B.F., Linthicum D.S. Expression of mRNA for 55-kDa and 75-kDa tumor necrosis factor (TNF) receptors in mouse cerebrovascular endothelium: effects of interleukin-1 beta, interferon-gamma and TNF-alpha on cultured cells. J. Neuroimmunol. 1995, 62:161-167.
6. Bennett J.L., Blanchet M.R., Zhao L., Zbytnuik L., Antignano F., Gold M., Kubes P., McNagny K.M. Bone marrow-derived mast cells accumulate in the central nervous system during inflammation but are dispensable for experimental autoimmune encephalomyelitis pathogenesis. J. Immunol. 2009, 182:5507-5514.
7. Bluthe R.M., Michaud B., Kelley K.W., Dantzer R. Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport 1996, 7:2823-2827.
8. Boche D., Perry V.H., Nicoll J.A. Review: activation patterns of microglia and their identification in the human brain. Neuropathol. Appl. Neurobiol. 2013, 39:3-18.
9. Bradl M., Lassmann H. Progressive multiple sclerosis. Semin. Immunopathol. 2009, 31:455-465.
10. Breder C.D., Hazuka C., Ghayur T., Klug C., Huginin M., Yasuda K., Teng M., Saper C.B. Regional induction of tumor necrosis factor alpha expression in the mouse brain after systemic lipopolysaccharide administration. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:11393-11397.
11. Brocke S., Gaur A., Piercy C., Gautam A., Gijbels K., Fathman C.G., Steinman L. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 1993, 365:642-644.
12. Brosnan C.F., Cannella B., Battistini L., Raine C.S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995, 45:S16-S21.
13. Buljevac D., Flach H.Z., Hop W.C., Hijdra D., Laman J.D., Savelkoul H.F., van Der Meche F.G., van Doorn P.A., Hintzen R.Q. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002, 125:952-960.
14. Campbell S.J., Anthony D.C., Oakley F., Carlsen H., Elsharkawy A.M., Blomhoff R., Mann D.A. Hepatic nuclear factor kappa B regulates neutrophil recruitment to the injured brain. J. Neuropathol. Exp. Neurol. 2008, 67:223-230.
15. Campbell S.J., Zahid I., Losey P., Law S., Jiang Y., Bilgen M., van Rooijen N., Morsali D., Davis A.E., Anthony D.C. Liver Kupffer cells control the magnitude of the inflammatory response in the injured brain and spinal cord. Neuropharmacology 2008, 55:780-787.
16. Carlson T., Kroenke M., Rao P., Lane T.E., Segal B. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J. Exp. Med. 2008, 205:811-823.
17. Chabas D., Ness J., Belman A., Yeh E.A., Kuntz N., Gorman M.P., Strober J.B., De Kouchkovsky I., McCulloch C., Chitnis T., Rodriguez M., Weinstock-Guttman B., Krupp L.B., Waubant E. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 2010, 74:399-405.
18. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354:610-621.
19. Chen J., Buchanan J.B., Sparkman N.L., Godbout J.P., Freund G.G., Johnson R.W. Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav. Immun. 2008, 22:301-311.
20. Ching S., Zhang H., Lai W., Quan N. Peripheral injection of lipopolysaccharide prevents brain recruitment of leukocytes induced by central injection of interleukin-1. Neuroscience 2006, 137:717-726.
21. Ching S., Zhang H., Belevych N., He L., Lai W., Pu X.A., Jaeger L.B., Chen Q., Quan N. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J. Neurosci. 2007, 27:10476-10486.
22. Combrinck M.I., Perry V.H., Cunningham C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience 2002, 112:7-11.
23. Comi G., Filippi M. Clinical trials in multiple sclerosis: methodological issues. Curr. Opin. Neurol. 2005, 18:245-252.
24. Correale J., Farez M.F. The impact of environmental infections (parasites) on MS activity. Mult. Scler. 2011, 17:1162-1169.
25. Correale J., Farez M.F. The impact of parasite infections on the course of multiple sclerosis. J. Neuroimmunol. 2011, 233:6-11.
26. Cunningham C.L., Niehus J.S., Bachtold J.F. Ambient temperature effects on taste aversion conditioned by ethanol: contribution of ethanol-induced hypothermia. Alcohol. Clin. Exp. Res. 1992, 16:1117-1124.
27. Cunningham C., Wilcockson D.C., Boche D., Perry V.H. Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease. J. Virol. 2005, 79:5174-5184.
28. Cunningham C., Wilcockson D.C., Campion S., Lunnon K., Perry V.H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 2005, 25:9275-9284.
29. Cunningham C., Campion S., Lunnon K., Murray C.L., Woods J.F., Deacon R.M., Rawlins J.N., Perry V.H. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol. Psychiatry 2009, 65:304-312.
30. Dantzer R., Bluthe R.M., Laye S., Bret-Dibat J.L., Parnet P., Kelley K.W. Cytokines and sickness behavior. Ann. N. Y. Acad. Sci. 1998, 840:586-590.
31. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
32. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
33. Dujmovic I., Mangano K., Pekmezovic T., Quattrocchi C., Mesaros S., Stojsavljevic N., Nicoletti F., Drulovic J. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: the elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J. Neuroimmunol. 2009, 207:101-106.
34. Ek M., Kurosawa M., Lundeberg T., Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J. Neurosci. 1998, 18:9471-9479.
35. Ericsson A., Liu C., Hart R.P., Sawchenko P.E. Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J. Comp. Neurol. 1995, 361:681-698.
36. Ferrari C.C., Tarelli R. Parkinson's disease and systemic inflammation. Park. Dis. 2011, 2011:436813.
37. Ferrari C.C., Depino A.M., Prada F., Muraro N., Campbell S., Podhajcer O., Perry V.H., Anthony D.C., Pitossi F.J. Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am. J. Pathol. 2004, 165:1827-1837.
38. Fiala M., Chattopadhay M., La Cava A., Tse E., Liu G., Lourenco E., Eskin A., Liu P.T., Magpantay L., Tse S., Mahanian M., Weitzman R., Tong J., Nguyen C., Cho T., Koo P., Sayre J., Martinez-Maza O., Rosenthal M.J., Wiedau-Pazos M. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J. Neuroinflammation 2010, 7:76.
39. Fung A., Vizcaychipi M., Lloyd D., Wan Y., Ma D. Central nervous system inflammation in disease related conditions: mechanistic prospects. Brain Res. 2012, 1446:144-155.
40. Furlan R., Bergami A., Brambilla E., Butti E., De Simoni M.G., Campagnoli M., Marconi P., Comi G., Martino G. HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 2007, 14:93-98.
41. Godoy M.C., Tarelli R., Ferrari C.C., Sarchi M.I., Pitossi F.J. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008, 131:1880-1894.
42. Goehler L.E., Gaykema R.P., Nguyen K.T., Lee J.E., Tilders F.J., Maier S.F., Watkins L.R. Interleukin-1beta in immune cells of the abdominal vagus nerve: a link between the immune and nervous systems?. J. Neurosci. 1999, 19:2799-2806.
43. Grammas P., Martinez J., Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev. Mol. Med. 2011, 13:e19.
44. Hartung H.P., Kieseier B.C., Hemmer B. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. J. Neurol. 2005, 252(Suppl. 5):v30-v37.
45. Hauser S.L., Doolittle T.H., Lincoln R., Brown R.H., Dinarello C.A. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990, 40:1735-1739.
46. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., Sheridan J.F., Godbout J.P. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J. Neuroinflammation 2008, 5:15.
47. Henry C.J., Huang Y., Wynne A.M., Godbout J.P. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav. Immun. 2009, 23:309-317.
48. Herges K., de Jong B.A., Kolkowitz I., Dunn C., Mandelbaum G., Ko R.M., Maini A., Han M.H., Killestein J., Polman C., Goodyear A.L., Dunn J., Steinman L., Axtell R.C. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult. Scler. 2012, 18:398-408.
49. Hiremath M.M., Chen V.S., Suzuki K., Ting J.P., Matsushima G.K. MHC class II exacerbates demyelination in vivo independently of T cells. J. Neuroimmunol. 2008, 203:23-32.
50. Holmes C., Cunningham C., Zotova E., Woolford J., Dean C., Kerr S., Culliford D., Perry V.H. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73:768-774.
51. Howe C.L., Mayoral S., Rodriguez M. Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1beta. Neurobiol. Dis. 2006, 23:731-739.
52. Jedrzejowska-Szypulka H., Straszak G., Larysz-Brysz M., Karpe J., Marcol W., Olakowska E., Woszczycka-Korczynska I., Lewin-Kowalik J. Interleukin-1beta plays a role in the activation of peripheral leukocytes after blood-brain barrier rupture in the course of subarachnoid hemorrhage. Curr. Neurovasc. Res. 2010, 7:39-48.
53. Kanwar J.R. Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr. Med. Chem. 2005, 12:2947-2962.
54. Kassiotis G., Kollias G. TNF and receptors in organ-specific autoimmune disease: multi-layered functioning mirrored in animal models. J. Clin. Invest. 2001, 107:1507-1508.
55. Kieseier B.C., Hemmer B., Hartung H.P. Multiple sclerosis-novel insights and new therapeutic strategies. Curr. Opin. Neurol. 2005, 18:211-220.
56. Konsman J.P., Kelley K., Dantzer R. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta and inducible nitric oxide synthase in rat brain. Neuroscience 1999, 89:535-548.
57. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002, 25:154-159.
58. Konsman J.P., Vigues S., Mackerlova L., Bristow A., Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J. Comp. Neurol. 2004, 472:113-129.
59. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
60. Kruger P.G., Bo L., Myhr K.M., Karlsen A.E., Taule A., Nyland H.I., Mork S. Mast cells and multiple sclerosis: a light and electron microscopic study of mast cells in multiple sclerosis emphasizing staining procedures. Acta Neurol. Scand. 1990, 81:31-36.
61. Larochelle C., Alvarez J.I., Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis?. FEBS Lett. 2011, 585:3770-3780.
62. Larsen P.J., Moller M., Mikkelsen J.D. Efferent projections from the periventricular and medial parvicellular subnuclei of the hypothalamic paraventricular nucleus to circumventricular organs of the rat: a Phaseolus vulgaris-leucoagglutinin (PHA-L) tracing study. J. Comp. Neurol. 1991, 306:462-479.
63. Li Q., Powell N., Zhang H., Belevych N., Ching S., Chen Q., Sheridan J., Whitacre C., Quan N. Endothelial IL-1R1 is a critical mediator of EAE pathogenesis. Brain Behav. Immun. 2011, 25:160-167.
64. Lindquist S., Hassinger S., Lindquist J.A., Sailer M. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Mult. Scler. 2011, 17:851-866.
65. Liu L., Belkadi A., Darnall L., Hu T., Drescher C., Cotleur A.C., Padovani-Claudio D., He T., Choi K., Lane T.E., Miller R.H., Ransohoff R.M. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 2010, 13:319-326.
66. Liu G., Fiala M., Mizwicki M.T., Sayre J., Magpantay L., Siani A., Mahanian M., Chattopadhyay M., La Cava A., Wiedau-Pazos M. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am. J. Neurodegener. Dis. 2012, 1:60-74.
67. Liu L., Li M., Spangler L.C., Spear C., Veenstra M., Darnall L., Chang C., Cotleur A.C., Ransohoff R.M. Functional defect of peripheral neutrophils in mice with induced deletion of CXCR2. Genesis 2013, 51:587-595.
68. Loma I., Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr. Neuropharmacol. 2011, 9:409-416.
69. Ludigs K., Parfenov V., Du Pasquier R.A., Guarda G. Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cell. Mol. Life Sci. 2012, 69:3395-3418.
70. Maimone D., Gregory S., Arnason B.G., Reder A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 1991, 32:67-74.
71. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 2008, 9:641-649.
72. Matsuki T., Nakae S., Sudo K., Horai R., Iwakura Y. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int. Immunol. 2006, 18:399-407.
73. McQuaid S., Cunnea P., McMahon J., Fitzgerald U. The effects of blood-brain barrier disruption on glial cell function in multiple sclerosis. Biochem. Soc. Trans. 2009, 37:329-331.
74. Mizwicki M.T., Fiala M., Magpantay L., Aziz N., Sayre J., Liu G., Siani A., Chan D., Martinez-Maza O., Chattopadhyay M., La Cava A. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am. J. Neurodegener. Dis. 2012, 1:305-315.
75. Moreno B., Jukes J.P., Vergara-Irigaray N., Errea O., Villoslada P., Perry V.H., Newman T.A. Systemic inflammation induces axon injury during brain inflammation. Ann. Neurol. 2011, 70:932-942.
76. Murta V., Ferrari C.C. Influence of Peripheral inflammation on the progression of multiple sclerosis: evidence from the clinic and experimental animal models. Mol. Cell. Neurosci. 2013, 53:6-13.
77. Murta V., Pitossi F.J., Ferrari C.C. CNS response to a second pro-inflammatory event depends on whether the primary demyelinating lesion is active or resolved. Brain Behav. Immun. 2012, 26:1102-1115.
78. Nadeau S., Rivest S. Regulation of the gene encoding tumor necrosis factor alpha (TNF-alpha) in the rat brain and pituitary in response in different models of systemic immune challenge. J. Neuropathol. Exp. Neurol. 1999, 58:61-77.
79. Naegele M., Tillack K., Reinhardt S., Schippling S., Martin R., Sospedra M. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J. Neuroimmunol. 2011, 242:60-71.
80. Omari K.M., John G., Lango R., Raine C.S. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 2006, 53:24-31.
81. Palma J.P., Park S.H., Kim B.S. Treatment with lipopolysaccharide enhances the pathogenicity of a low-pathogenic variant of Theiler's murine encephalomyelitis virus. J. Neurosci. Res. 1996, 45:776-785.
82. Pang Y., Fan L.W., Zheng B., Cai Z., Rhodes P.G. Role of interleukin-6 in lipopolysaccharide-induced brain injury and behavioral dysfunction in neonatal rats. Neuroscience 2006, 141:745-755.
83. Panitch H.S. Influence of infection on exacerbations of multiple sclerosis. Ann. Neurol. 1994, 36:S25-S28. (Suppl.).
84. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Orlando, FL.
85. Pelletier M., Maggi L., Micheletti A., Lazzeri E., Tamassia N., Costantini C., Cosmi L., Lunardi C., Annunziato F., Romagnani S., Cassatella M.A. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010, 115:335-343.
86. Penderis J., Woodruff R.H., Lakatos A., Li W.W., Dunning M.D., Zhao C., Marchionni M., Franklin R.J. Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS. Eur. J. Neurosci. 2003, 18:2253-2264.
87. Perry V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav. Immun. 2004, 18:407-413.
88. Perry V.H., Linden R. Evidence for dendritic competition in the developing retina. Nature 1982, 297:683-685.
89. Perry V., Cunningham C., Boche D. Atypical inflammation in the central nervous system in prion disease. Curr. Opin. Neurol. 2002, 15:349-354.
90. Perry V.H., Newman T.A., Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat. Rev. Neurosci. 2003, 4:103-112.
91. Perry V.H., Cunningham C., Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol. 2007, 7:161-167.
92. Pott Godoy M.C., Tarelli R., Ferrari C.C., Sarchi M.I., Pitossi F.J. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008, 131:1880-1894.
93. Pott Godoy M.C., Ferrari C.C., Pitossi F.J. Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression. J. Neuroimmunol. 2010, 222:29-39.
94. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11294-11298.
95. Quan N. Immune-to-brain signaling: how important are the blood-brain barrier-independent pathways?. Mol. Neurobiol. 2008, 37:142-152.
96. Quan N., Whiteside M., Herkenham M. Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience 1998, 83:281-293.
97. Ransohoff R.M., Brown M.A. Innate immunity in the central nervous system. J. Clin. Invest. 2012, 122:1164-1171.
98. Ruggiero V. Involvement of IL-1R/TLR signalling in experimental autoimmune encephalomyelitis and multiple sclerosis. Curr. Mol. Med. 2011, 12:218-236.
99. Sayed B.A., Christy A.L., Walker M.E., Brown M.A. Meningeal mast cells affect early T cell central nervous system infiltration and blood-brain barrier integrity through TNF: a role for neutrophil recruitment?. J. Immunol. 2010, 184:6891-6900.
100. Scheirer C.J., Ray W.S., Hare N. The analysis of ranked data derived from completely randomized factorial designs. Biometrics 1976, 32:429-434.
101. Schiffenbauer J., Johnson H.M., Butfiloski E.J., Wegrzyn L., Soos J.M. Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8543-8546.
102. Schiffenbauer J., Streit W.J., Butfiloski E., LaBow M., Edwards C., Moldawer L.L. The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor. Clin. Immunol. 2000, 95:117-123.
103. Secor V.H., Secor W.E., Gutekunst C.A., Brown M.A. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 2000, 191:813-822.
104. Selmaj K.W., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 1988, 23:339-346.
105. Serres S., Anthony D.C., Jiang Y., Broom K.A., Campbell S.J., Tyler D.J., van Kasteren S.I., Davis B.G., Sibson N.R. Systemic inflammatory response reactivates immune-mediated lesions in rat brain. J. Neurosci. 2009, 29:4820-4828.
106. Simi A., Tsakiri N., Wang P., Rothwell N.J. Interleukin-1 and inflammatory neurodegeneration. Biochem. Soc. Trans. 2007, 35:1122-1126.
107. Skelly D.T., Hennessy E., Dansereau M.A., Cunningham C. A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1beta, TNF-alpha and IL-6 challenges in C57BL/6 mice. PLoS One 2013, 8:e69123.
108. Sly L.M., Krzesicki R.F., Brashler J.R., Buhl A.E., McKinley D.D., Carter D.B., Chin J.E. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. Bull. 2001, 56:581-588.
109. Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006, 203:1685-1691.
110. Teeling J.L., Perry V.H. Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 2009, 158:1062-1073.
111. Teeling J.L., Cunningham C., Newman T.A., Perry V.H. The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: implications for a role of COX-1. Brain Behav. Immun. 2010, 24:409-419.
112. Tsukada N., Miyagi K., Matsuda M., Yanagisawa N., Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurol. Sci. 1991, 104:230-234.
113. Vallieres L., Rivest S. Regulation of the genes encoding interleukin-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine interleukin-1beta. J. Neurochem. 1997, 69:1668-1683.
114. Vallieres L., Rivest S. Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. Endocrinology 1999, 140:3890-3903.
115. Vallieres N., Berard J.L., David S., Lacroix S. Systemic injections of lipopolysaccharide accelerates myelin phagocytosis during Wallerian degeneration in the injured mouse spinal cord. Glia 2006, 53:103-113.
116. Van Dam A.M., De Vries H.E., Kuiper J., Zijlstra F.J., De Boer A.G., Tilders F.J., Berkenbosch F. Interleukin-1 receptors on rat brain endothelial cells: a role in neuroimmune interaction?. FASEB J. 1996, 10:351-356.
117. Veenstra M., Ransohoff R.M. Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?. J. Neuroimmunol. 2012, 246:1-9.
118. Warabi Y., Matsumoto Y., Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J. Neurol. Sci. 2007, 252:57-61.
119. Watzlawik J., Warrington A.E., Rodriguez M. Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination. Expert. Rev. Neurother. 2010, 10:441-457.
120. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:239-248.
121. Williams A., Piaton G., Lubetzki C. Astrocytes-friends or foes in multiple sclerosis?. Glia 2007, 55:1300-1312.
122. Wilson E.H., Weninger W., Hunter C.A. Trafficking of immune cells in the central nervous system. J. Clin. Invest. 2010, 120:1368-1379.
123. Wu F., Cao W., Yang Y., Liu A. Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 mice. Histochem. Cell Biol. 2010, 133:313-322.
124. Ysrraelit M.C., Gaitan M.I., Lopez A.S., Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology 2008, 71:1948-1954.
125. Zeis T., Graumann U., Reynolds R., Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008, 131:288-303.